Inspire Medical Systems, Inc.INSPEarnings & Financial Report
Inspire Medical Systems, Inc. is a medical technology firm that develops, manufactures and commercializes implantable neurostimulation solutions for obstructive sleep apnea. Its core product serves patients intolerant to CPAP therapy, with main markets across North America, Europe, and select Asia-Pacific regions, operating in sleep medicine and otolaryngology segments.
Revenue
$217.1M
Gross Profit
$182.4M
Operating Profit
$-3.3M
Net Profit
$-3.6M
Gross Margin
84.0%
Operating Margin
-1.5%
Net Margin
-1.7%
YoY Growth
10.8%
EPS
$-0.12
Inspire Medical Systems, Inc. Q2 FY2025 Financial Summary
Inspire Medical Systems, Inc. reported revenue of $217.1M (up 10.8% YoY) for Q2 FY2025, with a net profit of $-3.6M (down 136.7% YoY) (-1.7% margin). Cost of goods sold was $34.7M, operating expenses totaled $185.7M.
Key Financial Metrics
| Total Revenue | $217.1M |
|---|---|
| Net Profit | $-3.6M |
| Gross Margin | 84.0% |
| Operating Margin | -1.5% |
| Report Period | Q2 FY2025 |
Inspire Medical Systems, Inc. Annual Revenue by Year
Inspire Medical Systems, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $912.0M).
| Year | Annual Revenue |
|---|---|
| 2025 | $912.0M |
| 2024 | $802.8M |
| 2023 | $624.8M |
| 2022 | $407.9M |
Inspire Medical Systems, Inc. Quarterly Revenue & Net Profit History
Inspire Medical Systems, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $204.6M | +1.6% | N/A | N/A |
| Q4 FY2025 | $269.1M | +12.2% | $136.1M | 50.6% |
| Q3 FY2025 | $224.5M | +10.5% | $9.9M | 4.4% |
| Q2 FY2025 | $217.1M | +10.8% | $-3.6M | -1.7% |
| Q1 FY2025 | $201.3M | +22.7% | $3.0M | 1.5% |
| Q4 FY2024 | $239.7M | +24.5% | $35.2M | 14.7% |
| Q3 FY2024 | $203.2M | +32.5% | $18.5M | 9.1% |
| Q2 FY2024 | $195.9M | +29.6% | $9.8M | 5.0% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $195.9M | $203.2M | $239.7M | $201.3M | $217.1M | $224.5M | $269.1M | $204.6M |
| YoY Growth | 29.6% | 32.5% | 24.5% | 22.7% | 10.8% | 10.5% | 12.2% | 1.6% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $728.4M | $796.2M | $808.4M | $730.8M | $802.2M | $807.7M | $907.3M | $911.4M |
| Liabilities | $90.3M | $99.6M | $118.7M | $95.1M | $124.4M | $141.3M | $126.2M | $119.0M |
| Equity | $638.1M | $696.6M | $689.7M | $635.7M | $677.8M | $666.5M | $781.2M | $792.3M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-78000 | $52.3M | $69.2M | $-6.7M | $2.7M | $68.5M | $52.5M |